Scott Ward Purchases 15,995 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward purchased 15,995 shares of the stock in a transaction dated Wednesday, May 6th. The shares were acquired at an average price of $1.15 per share, for a total transaction of $18,394.25. Following the acquisition, the director directly owned 163,841 shares of the company’s stock, valued at $188,417.15. This represents a 10.82% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

InspireMD Trading Down 0.9%

Shares of NSPR stock opened at $1.15 on Friday. InspireMD, Inc. has a 1-year low of $1.02 and a 1-year high of $2.93. The company has a market capitalization of $53.93 million, a price-to-earnings ratio of -1.53 and a beta of 0.82. The stock’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in InspireMD in the fourth quarter valued at about $30,000. Virtu Financial LLC purchased a new position in InspireMD in the fourth quarter valued at about $31,000. Creative Planning purchased a new position in InspireMD in the second quarter valued at about $44,000. Uniting Wealth Partners LLC purchased a new position in InspireMD in the third quarter valued at about $51,000. Finally, Legato Capital Management LLC acquired a new stake in shares of InspireMD in the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Loop Capital set a $5.00 price target on InspireMD in a report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a report on Tuesday. Lake Street Capital set a $4.00 price target on InspireMD in a report on Monday, May 4th. Finally, Maxim Group assumed coverage on InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, InspireMD presently has a consensus rating of “Buy” and a consensus target price of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.